Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14


Assessment of Quality of Life and Treatment Outcomes of Patients With Persistent Postchemotherapy Alopecia.

Freites-Martinez A, Chan D, Sibaud V, Shapiro J, Fabbrocini G, Tosti A, Cho J, Goldfarb S, Modi S, Gajria D, Norton L, Paus R, Cigler T, Lacouture ME.

JAMA Dermatol. 2019 Jun 1;155(6):724-728. doi: 10.1001/jamadermatol.2018.5071. Erratum in: JAMA Dermatol. 2019 Apr 10;:.


Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer.

Freites-Martinez A, Shapiro J, Chan D, Fornier M, Modi S, Gajria D, Dusza S, Goldfarb S, Lacouture ME.

JAMA Dermatol. 2018 Jun 1;154(6):670-675. doi: 10.1001/jamadermatol.2018.0454.


The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.

Soumerai JD, Zelenetz AD, Moskowitz CH, Palomba ML, Hamlin PA Jr, Noy A, Straus DJ, Moskowitz AJ, Younes A, Matasar MJ, Horwitz SM, Portlock CS, Konner JA, Gounder MM, Hyman DM, Voss MH, Fury MG, Gajria D, Carvajal RD, Ho AL, Beumer JH, Kiesel B, Zhang Z, Chen A, Little RF, Jarjies C, Dang TO, France F, Mishra N, Gerecitano JF.

Clin Cancer Res. 2017 Aug 1;23(15):4119-4126. doi: 10.1158/1078-0432.CCR-16-3068. Epub 2017 Mar 17.


Decreased gastrointestinal toxicity associated with a novel capecitabine schedule (7 days on and 7 days off): a systematic review.

Cadoo KA, Gajria D, Suh E, Patil S, Theodoulou M, Norton L, Hudis CA, Traina TA.

NPJ Breast Cancer. 2016 Mar 30;2:16006. doi: 10.1038/npjbcancer.2016.6. eCollection 2016.


A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer.

Iyengar NM, Fornier MN, Sugarman SM, Theodoulou M, Troso-Sandoval TA, D'Andrea GM, Drullinsky PR, Gajria D, Goldfarb SB, Comen EA, Lake DE, Modi S, Traina TA, Lacouture ME, Chen MF, Patil S, Baselga J, Norton L, Hudis CA, Dang CT.

Clin Breast Cancer. 2016 Apr;16(2):87-94. doi: 10.1016/j.clbc.2015.09.009. Epub 2015 Sep 25.


Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

Dang C, Iyengar N, Datko F, D'Andrea G, Theodoulou M, Dickler M, Goldfarb S, Lake D, Fasano J, Fornier M, Gilewski T, Modi S, Gajria D, Moynahan ME, Hamilton N, Patil S, Jochelson M, Norton L, Baselga J, Hudis C.

J Clin Oncol. 2015 Feb 10;33(5):442-7. doi: 10.1200/JCO.2014.57.1745. Epub 2014 Dec 29. Erratum in: J Clin Oncol. 2019 Feb 1;37(4):354.


A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors.

Hudis C, Swanton C, Janjigian YY, Lee R, Sutherland S, Lehman R, Chandarlapaty S, Hamilton N, Gajria D, Knowles J, Shah J, Shannon K, Tetteh E, Sullivan DM, Moreno C, Yan L, Han HS.

Breast Cancer Res. 2013 Nov 19;15(6):R110. doi: 10.1186/bcr3577.


High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML).

Larson SM, Campbell NP, Huo D, Artz A, Zhang Y, Gajria D, Green M, Weiner H, Daugherty C, Odenike O, Godley LA, Hyjek E, Gurbuxani S, Thirman M, Sipkins D, Van Besien K, Larson RA, Stock W.

Leuk Lymphoma. 2012 Mar;53(3):445-50. doi: 10.3109/10428194.2011.621562.


Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.

Gajria D, Gonzalez J, Feigin K, Patil S, Chen C, Theodoulou M, Drullinsky P, D'Andrea G, Lake D, Norton L, Hudis CA, Traina TA.

Breast Cancer Res Treat. 2012 Jan;131(1):111-6. doi: 10.1007/s10549-011-1749-y. Epub 2011 Sep 4.


Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer.

Gajria D, Feigin K, Tan LK, Patil S, Geneus S, Theodoulou M, Norton L, Hudis CA, Traina TA.

Cancer. 2011 Sep 15;117(18):4125-31. doi: 10.1002/cncr.25992. Epub 2011 Mar 8.


HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.

Gajria D, Chandarlapaty S.

Expert Rev Anticancer Ther. 2011 Feb;11(2):263-75. doi: 10.1586/era.10.226. Review.


Adjuvant taxanes: more to the story.

Gajria D, Seidman A, Dang C.

Clin Breast Cancer. 2010 Sep;10 Suppl 2:S41-9. doi: 10.3816/CBC.2010.s.011. Review.


Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.

Odenike OM, Larson RA, Gajria D, Dolan ME, Delaney SM, Karrison TG, Ratain MJ, Stock W.

Invest New Drugs. 2008 Jun;26(3):233-9. doi: 10.1007/s10637-008-9115-6. Epub 2008 Jan 24.


Caspase activation is required for gemcitabine activity in multiple myeloma cell lines.

Nabhan C, Gajria D, Krett NL, Gandhi V, Ghias K, Rosen ST.

Mol Cancer Ther. 2002 Nov;1(13):1221-7.

Supplemental Content

Loading ...
Support Center